TAAV Biomanufacturing Solutions, S.L.U. (TAAV), a subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG.
TAAV manufactures and offers neDNA™ to the international market: enzymatic DNA used for gene therapies with adeno-associated viruses (AAV).
neDNA™, the enzymatic DNA produced by TAAV, is an alternative to plasmid DNA, commonly used in the production of AAVs, and its main advantage lies in higher yields of genetic material: DNA. It significantly shortens production timelines and enables faster AAV production with a higher safety profile by eliminating residual bacterial sequences from plasmid DNA.
TAAV was founded in 2019 and became fully owned by AskBio in 2022. The company's headquarters, as well as its production plant and laboratories, are located in San Sebastián, Spain.
The company offers this innovative enzymatic DNA solution to the biopharmaceutical and gene therapy industries. Gene therapy is applied to congenital diseases that affect a single gene and involves replacing the altered gene that is not functioning properly or is missing in the person and therefore not fulfilling its function. To do this, a vehicle is needed to transport the correct gene to the cells in the body. Adeno-associated viruses (AAVs) have shown great potential in this area by optically delivering the gene of interest with the advantage that they do not reproduce in the body and do not cause associated infections.
CEO
Dolores Baksh
COO
Alfredo Martínez
DIVESTED COMPANY
2018–2019 (Acquired by Asklepios Biopharmaceuticals (AskBio) and Bayer AG)
DETAILS
TAAV Biomanufacturing Solutions
Gipuzkoa Science and Technology Park
Paseo Mikeletegi, 73 B
20009 – Donostia – San Sebastián
